Alkem Laboratories Limited
All news and filings related to Alkem Laboratories Limited.
View all news & filings- Low impact
Alkem Labs Incorporates Wholly Owned Subsidiary in UAE for Product Manufacturing
Alkem Laboratories Limited has incorporated a wholly-owned subsidiary, Alkem Pharmaceuticals Scientific Office FZ LLC, in Dubai Healthcare City, UAE. This subsidiary will focus on product manufacturing and obtaining registrations. The authorized and subscribed capital is AED 3,670,000, with Alkem acquiring 100% ownership.
Read the summary - Low impact
Alkem Labs Appoints Samsher Kumar Deo as Senior Management Personnel
Alkem Laboratories has appointed Mr. Samsher Kumar Deo to a senior management role, effective March 27, 2026. Mr. Deo has over 29 years of experience in sales functions and holds a B.Sc. degree.
Read the summary - Low impact
Alkem Laboratories: Trading Window Closure Announced for Q4FY26 Results
Alkem Laboratories will close its trading window from March 30, 2026. The window will reopen 48 hours after the announcement of the financial results for the quarter and year ended March 31, 2026.
Read the summary - Medium impact
Alkem Labs Launches Semaglutide Injection in India Starting at ₹450/Week
Alkem Laboratories has launched semaglutide injection in India for type-2 diabetes and weight management. The weekly therapy starts at ₹450, with a month's dosage priced at ₹1,800. The company received DCGI approval and aims to improve access to this treatment.
Read the summary - Medium impact
Alkem Labs receives EU GMP Certificate for Daman facility from Malta Medicines Authority
Alkem Laboratories has received an EU GMP Certificate from the Malta Medicines Authority for its Daman manufacturing facility. The certificate is valid for three years from December 9th, 2025.
Read the summary - Low impact
Alkem Laboratories Schedules Investor Meeting on March 26, 2026
Alkem Laboratories Limited will hold a virtual meeting with Millennium Capital Management on March 26, 2026. This is part of the company's investor engagement activities.
Read the summary - Medium impact
Alkem Labs to Invest ₹533 Crore in New Greenfield Manufacturing Facility in Ujjain
Alkem Laboratories will invest up to ₹533 crore in a new greenfield formulations manufacturing facility in Ujjain, Madhya Pradesh. The company secured 30 acres of land via an allotment letter dated March 18, 2026, from DMIC Vikram Udyogpuri Limited.
Read the summary - Medium impact
Alkem Laboratories receives EU GMP Certificate for Baddi facility
Alkem Laboratories received an EU GMP Certificate for its Baddi manufacturing facility from Germany's Department of Pharmacy. The certificate is valid for three years post-inspection, which occurred from Nov 4-10, 2025.
Read the summary - Medium impact
Alkem Medtech Executes Share Purchase Agreement to Acquire Occlutech Holding AG
Alkem Medtech, a subsidiary of Alkem Laboratories, has executed a Share Purchase Agreement to acquire 51% to 55% of Switzerland-based Occlutech Holding AG. The agreement was signed on March 6, 2026.
Read the summary - Low impact
Alkem Labs posts video recording of Investor Meet on Alkem MedTech's strategic way forward.
Alkem Laboratories Limited has released the video recording of an investor meet discussing Alkem MedTech's strategic path forward. The recording is available on the company's website.
Read the summary - High impact
Alkem Labs to Acquire 51-55% Stake in Occlutech for €180.70 Mn
Alkem MedTech will acquire a 51-55% stake in Occlutech Holding AG for €180.70 million (Rs. 19,516 million). The transaction is expected to close by June 2026. This strategic move aims to expand Alkem MedTech's presence in the global cardiovascular market. The company also provided updates on its Orthopedics segment, targeting significant implant growth.
Read the summary - Low impact
Alkem Labs to Hold Investor Meetings on Feb 25-26, 2026
Alkem Laboratories will hold in-person investor meetings on February 25th and 26th, 2026, in Mumbai. These include a one-on-one meet at the Kotak - Chasing Growth 2026 conference and participation in the IIFL 17th Entrepreneurial India Conference 2026. The schedule is subject to change.
Read the summary - High impact
Alkem Laboratories to Acquire 51-55% Stake in Occlutech for €180.70 Mn
Alkem Laboratories will acquire a 51-55% stake in Occlutech Holding AG for €180.70 million (₹1,951.6 crore). The deal, expected by June 2026, aims to expand Alkem MedTech's global cardiovascular business. Occlutech is a leading player in the structural heart occluder market. Funding will come from internal accruals.
Read the summary - High impact
Alkem Labs Q3 FY26 Earnings Call Transcript Released; Enters MedTech with Occlutech Acquisition
Alkem Laboratories reported Q3 FY26 revenue of ₹3,736.8 crore, up 10.7% YoY. The company announced its entry into the medical devices sector by acquiring a 55% stake in Occlutech for an investment of ₹200-300 crore over 3-4 years. Occlutech is expected to achieve 20-25% EBITDA margins within 3-5 years. Domestic sales grew 5.5% to ₹2,495.9 crore.
Read the summary - Medium impact
Alkem Labs Subsidiary Enzene Biosciences Completes USFDA Inspection with 6 Procedural Observations
Alkem Laboratories' subsidiary, Enzene Biosciences, completed a USFDA Pre-Approval Inspection on February 13, 2026. The inspection resulted in 6 procedural observations. Importantly, there were zero observations related to data integrity, highlighting strong quality systems. Enzene is preparing its response and corrective actions.
Read the summary - Low impact
Alkem Laboratories Publishes Newspaper Ad for Q3 FY26 Financial Results
Alkem Laboratories Limited published a newspaper advertisement on February 14, 2026, announcing its Unaudited Financial Results for the quarter and nine months ended December 31, 2025. The results are also available on the company's website.
Read the summary - Medium impact
Alkem's Subsidiary Enzene Biosciences Receives 6 Procedural Observations from USFDA Inspection
Alkem's subsidiary, Enzene Biosciences, was inspected by the USFDA. The inspection resulted in 6 procedural observations. Importantly, there were zero observations related to data integrity, underscoring the robustness of Enzene's quality systems and regulatory filing reliability. Enzene is preparing its response to the USFDA.
Read the summary - Low impact
Alkem Laboratories to Host Investor Meet on Feb 18, 2026, for Alkem MedTech Strategy
Alkem Laboratories will host an investor meet on February 18, 2026, in Mumbai to present the strategic direction of Alkem MedTech. Senior leadership will attend to discuss future plans.
Read the summary - Medium impact
Alkem Labs Announces Record Date for Interim Dividend
Alkem Laboratories has set February 20, 2026, as the record date for its interim dividend. The dividend will be paid after March 11, 2026. The company also reported its financial results for the nine months ended December 31, 2025, with total income at ₹649.88 crore.
Read the summary - Low impact
Alkem Labs Q3&9MFY26 Earnings Conference Call Audio Recording Available
Alkem Laboratories Limited has made the audio recording of its Q3 and 9MFY26 Earnings Conference Call available on its website. Investors can access the recording for detailed insights into the company's financial performance during the period.
Read the summary - High impact
Alkem MedTech to acquire 55% stake in Occlutech for EUR 99.4M (₹1,074 Cr)
Alkem MedTech will acquire up to 55% of Occlutech Holding AG for EUR 99.4 million (approx. ₹1,074 crore). Occlutech specializes in minimally invasive cardiac implants and reported EUR 49.4 million revenue in CY25. The acquisition is expected to be completed by June 2026.
Read the summary - Low impact
Alkem Labs Postpones Q3FY26 Earnings Call Due to Participant Change
Alkem Laboratories Ltd. will hold its Q3FY26 and 9MFY26 financial results conference call on February 13, 2026, at 5:00 PM IST. There is a change in call participants. The call will feature MD, CEO, CFO, and CEO of Alkem MedTech.
Read the summary - Low impact
Alkem Laboratories: Trading Window Reopens February 16
Alkem Laboratories' trading window will reopen on February 16, 2026. The window was closed for the company's financial results for the quarter and nine months ended December 31, 2025, which were announced on February 13, 2026.
Read the summary - High impact
Alkem Labs Q3 FY26 Revenue Up 10.7% to ₹3,737 Crore; Acquires Majority Stake in Occlutech
Alkem Laboratories reported Q3 FY26 revenue of ₹3,737 crore, up 10.7% YoY. International sales surged 26.6% YoY. The company announced plans to acquire a majority stake in Occlutech Holding AG, a global medical devices company specializing in cardiac implants, to expand its Medtech business.
Read the summary - Medium impact
Alkem Labs to Acquire 51-55% Stake in Occlutech Holding AG for EUR 180.70 Million
Alkem Medtech Private Limited will acquire 51-55% of Occlutech Holding AG for EUR 180.70 million cash. Occlutech develops cardiac implants. The deal is expected to close by June 30, 2026. This acquisition marks Alkem's entry into the cardiovascular devices segment.
Read the summary - Low impact
Alkem Labs Approves Amendment to JV Shareholders Agreement for Saudi Arabia Subsidiary
Alkem Laboratories approved an amendment to its Saudi Arabia joint venture Shareholders' Agreement on February 13, 2026. Vitals Biotech Company, owned by the JV partner, will now hold 49% of the JV's share capital, replacing Mr. Abdulaziz Alsheikh directly.
Read the summary - Medium impact
Alkem Labs Subsidiary Enzene Biosciences Secures ₹26.16 Crore Funding
Alkem Laboratories' subsidiary, Enzene Biosciences, has entered into an agreement for a preferential allotment of securities. F-Prime Capital and ERVI Healthcare will invest ₹26.16 crore in Enzene for Series B CCPS and equity shares. This amendment also covers adherence to the Shareholders' Agreement and modifies certain provisions.
Read the summary - Medium impact
Alkem Labs Board Approves Amalgamation of Wholly-Owned Subsidiary Adroit Biomed
Alkem Laboratories' Board approved the amalgamation of its wholly-owned subsidiary, Adroit Biomed Limited. The scheme aims to integrate operations, reduce costs, and simplify the group structure. Adroit Biomed had a net worth of ₹75.7 Mn and revenue of ₹596.8 Mn as of March 31, 2025. No share consideration will be paid.
Read the summary - Medium impact
Alkem Laboratories Declares Interim Dividend of ₹43 per Share
Alkem Laboratories declared an interim dividend of ₹43 per equity share for FY2025-26. The company also approved its standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The dividend will be paid from March 6, 2026, with a record date of February 20, 2026.
Read the summary - Medium impact
Alkem Labs declares ₹43 interim dividend; Q3 FY26 results announced
Alkem Laboratories announced Q3 FY26 results, declaring an interim dividend of ₹43 per share. The record date is February 20, 2026. The company reported consolidated revenue of ₹111,089.5 million and profit after tax of ₹21,000.5 million for the nine months ended December 31, 2025. Standalone revenue was ₹74,054.7 million with a profit after tax of ₹19,680.6 million from continuing operations.
Read the summary - High impact
Alkem Laboratories Declares Interim Dividend of ₹43, Approves Q3 FY26 Results
Alkem Laboratories declared an interim dividend of ₹43 per share, payable March 6, 2026. The company reported Q3 FY26 revenue of ₹37,368 million, up 10.7% YoY. Net profit rose 1.6% to ₹6,360 million. Alkem also signed a term sheet to acquire a majority stake in Occlutech Holding AG.
Read the summary - Medium impact
Alkem Labs declares interim dividend of ₹43 per share; Q3 FY26 results announced
Alkem Laboratories declared an interim dividend of ₹43 per share for FY26, payable from March 6, 2026. The record date is February 20, 2026. The company also announced its financial results for the quarter and nine months ended December 31, 2025.
Read the summary - Low impact
Alkem Labs revises Q3FY26 earnings call to Feb 13, 5 PM IST
Alkem Laboratories Ltd. has rescheduled its Q3FY26 and 9MFY26 earnings conference call to Friday, February 13, 2026, at 5:00 PM IST. The results will be announced on the same day. Dr. Vikas Gupta (CEO) and Mr. Nitin Agrawal (CFO) will represent the company.
Read the summary - Low impact
Alkem Labs Subsidiary Amalgamation: Board Approves Scheme of Arrangement
Alkem Laboratories' subsidiary, Alkem Medtech Private Limited, approved the amalgamation of Alkem Medtech Ortho Private Limited. This scheme, approved on February 6, 2026, aims to consolidate operations, enhance efficiency, and reduce costs. No cash consideration is involved as it is a transfer between wholly-owned subsidiaries.
Read the summary - Low impact
Alkem Labs to discuss Q3FY26 results on Feb 13, 2026
Alkem Laboratories will hold a conference call on February 13, 2026, to discuss its Q3FY26 and 9MFY26 financial results. The call is scheduled from 4:00 PM to 5:00 PM IST. Management, including the CEO and CFO, will participate.
Read the summary - Low impact
Alkem Laboratories Receives GST Demand Order of ₹2.34 Crore
Alkem Laboratories received a GST demand order of ₹2.34 crore plus an equal amount for interest and penalty from the Goa GST authority for FY19-23. The company disputes the demand, alleging excess Input Tax Credit, and plans to appeal. Alkem states there is no material financial or operational impact.
Read the summary - Low impact
Alkem Labs Receives GST Demand Order of ₹3.83 Crore for FY18-20
Alkem Laboratories received a GST demand order for ₹3.83 crore plus penalty for FY18-20 from Chennai authorities. The company disputes the demand, citing correct tax discharge, and plans to appeal. No material financial or operational impact is expected.
Read the summary - Low impact
Alkem Launches Renocia Cyclical Therapy Kit for Hair Growth Support
Alkem Laboratories launched Renocia cyclical therapy, a vegetarian nutritional supplement kit for hair growth and loss management. Formulated separately for men and women, it follows a structured weekly regimen. This prescription product expands Alkem's dermatology portfolio.
Read the summary - Low impact
Alkem Labs Receives GST Demand Order of ₹2.17 Crore
Alkem Laboratories received a GST demand order from Lucknow CGST of ₹1.08 crore, with an equal penalty and interest, totaling ₹2.17 crore for FY19-FY21. The company disputes the demand, citing excess Input Tax Credit, and plans to appeal.
Read the summary - Medium impact
Alkem Labs receives ₹32.5 Cr balance consideration for trade generics business transfer
Alkem Laboratories received the balance sale consideration of ₹32.5 crore for its trade generics business transfer. The total sale consideration aggregates to ₹532.5 crore. The business was transferred to its wholly-owned subsidiary, Alkem Wellness, on a slump sale basis.
Read the summary - Low impact
Alkem Labs Receives GST Demand Order of ₹5.2 Lakhs for FY22
Alkem Laboratories received a GST demand order for FY21-22 from West Bengal authorities. The demand includes ₹5.2 lakhs in GST, ₹3.89 lakhs in interest, and ₹0.62 lakhs in penalty. The company disagrees with the order and plans to appeal, stating no material financial or operational impact.
Read the summary - Low impact
Alkem Labs Receives GST Demand Order of ₹7.89 Lakhs, Plans Appeal
Alkem Laboratories received a GST demand order for FY21-22, totaling ₹7,89,834/- plus ₹6,02,958/- interest and ₹78,984/- penalty. The company disputes the 'excess availment of Input Tax Credit' allegation and plans to appeal. No material financial impact is anticipated.
Read the summary - Low impact
Alkem Labs Receives GST Demand Order of ₹56.71 Lakhs for FY19
Alkem Laboratories received a GST demand order for FY19, including ₹21.94 Lakhs GST, ₹12.83 Lakhs interest, and ₹21.94 Lakhs penalty. The company disputes the demand and plans to appeal. No material financial or operational impact is expected.
Read the summary - Low impact
Alkem Labs Receives GST Demand Orders Totaling ₹1.89 Crore
Alkem Laboratories received two GST demand orders totaling ₹1.89 crore, including penalties and interest. The orders, received on December 26, 2025, allege excess ITC availment. The company disputes the demands and plans to appeal, stating no material financial impact.
Read the summary - Medium impact
Alkem Labs Acquires ₹300 Crore Stake in Subsidiary Enzene Biosciences
Alkem Laboratories acquired 64,02,018 equity shares in its subsidiary, Enzene Biosciences, for ₹299.99 crore. The acquisition aims to meet Enzene's capex and working capital needs. Enzene reported a turnover of ₹363.62 crore for FY25. Alkem's stake in Enzene increased to 99.61%.
Read the summary - Low impact
Alkem Labs Receives GST Order Demanding ₹2.05 Lakhs Plus Penalty & Interest
Alkem Laboratories received a GST order demanding ₹2,05,095 with ₹41,019 penalty and ₹1,35,733 interest for FY21-22. The company disputes the excess ITC availment allegation and plans to appeal. No material financial or operational impact is expected.
Read the summary - Low impact
Alkem Laboratories: Trading Window Closed from Dec 30, 2025
Alkem Laboratories' trading window will be closed from December 30, 2025. The closure extends until 48 hours after the announcement of financial results for the quarter and nine months ending December 31, 2025.
Read the summary - Low impact
Alkem Labs Schedules Analyst/Institutional Investor Meet on Dec 30
Alkem Laboratories Limited will hold an in-person, one-on-one meeting with 3P Investment Managers on December 30th, 2025, in Mumbai. The schedule is subject to change.
Read the summary - Low impact
Alkem Labs Appoints Sunil Sawant as Senior Management Personnel
Alkem Laboratories appointed Mr. Sunil Sawant as Senior Management Personnel, effective December 16, 2025. Mr. Sawant has over 33 years of experience in distribution and depot management.
Read the summary - Low impact
Alkem Labs Schedules Investor Meetings on Dec 18
Alkem Laboratories Limited will conduct one-on-one in-person investor meetings on December 18, 2025, in Mumbai. Participants include Tata Mutual Fund and Mahindra Manulife. The schedule is subject to change.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio